Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Current Deferred Revenue: 2014-2024

Historic Current Deferred Revenue for Capricor Therapeutics (CAPR) over the last 6 years, with Dec 2024 value amounting to $12.0 million.

  • Capricor Therapeutics' Current Deferred Revenue fell 8.61% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year decrease of 8.61%. This contributed to the annual value of $12.0 million for FY2024, which is 50.56% down from last year.
  • Latest data reveals that Capricor Therapeutics reported Current Deferred Revenue of $12.0 million as of FY2024, which was down 50.56% from $24.3 million recorded in FY2023.
  • In the past 5 years, Capricor Therapeutics' Current Deferred Revenue ranged from a high of $24.3 million in FY2023 and a low of $12.0 million during FY2024.
  • In the last 3 years, Capricor Therapeutics' Current Deferred Revenue had a median value of $18.0 million in 2022 and averaged $18.1 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 34.98% in 2023, then tumbled by 50.56% in 2024.
  • Over the past 3 years, Capricor Therapeutics' Current Deferred Revenue (Yearly) stood at $18.0 million in 2022, then spiked by 34.98% to $24.3 million in 2023, then plummeted by 50.56% to $12.0 million in 2024.